OBJECTIVES: To assess cost-effectiveness of PXF, used in combination with G-CSF versus standard mobilization options used alone, to enhance mobilization of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation (auto-HCT). Target population, as defined by Polish opinion leaders, are patients with NHL/HL or MM whose cells mobilize poorly, i.e. predicted poor mobilizers (peripheral blood CD34+ cell count <10/mL) and proven poor mobilizers (failure of previous mobilizations). METHODS: PXF is an add-on therapy to currently reimbursed standard mobilization (SM) options: G-CSF or chemotherapy plus G-CSF. Two scenarios were compared: with and without PXF. Analysis was performed using a Markov decision model, developed in TreeAge Pro 2013. A probabilistic (Monte Carlo simulation) model with time-dependent transition probabilities included initial cycle, during which the individual undergoes mobilization and auto-HCT if cell collection is successful, and four mutually exclusive health states: progression-free survival (remission and durable remission – lymphomas only), further treatment after progression, palliative treatment/observation and death. A one-year Markov cycle length was used with half-cycle correction. Baseline cohort characteristics, disease progression and utility estimates were obtained from systematic literature review and questionnaire study among Polish clinical practitioners. The analysis was conducted from the Polish public payer, patients, and societal perspective, over a lifetime horizon. Discount rates were 5% (costs) and 3.5% (outcomes). RESULTS: The mean QALY gain were 7,378 (PXF) and 6,452 (SM). The mean costs were 188,404 PLN (€45,019) (PXF) and 157,073 PLN (€37,532) (SM). Base-case incremental cost-utility ratio (ICUR) in NHL/HL/MM population was 33,821 PLN/QALY (€8,082). Probability of PXF being cost-effective in Poland when compared to SM is 99,8% (current threshold of 105,801 PLN/QALY (€25,281)). CONCLUSIONS: Based on accepted cost/QALY threshold values in the Polish settings, PXF was proved to be cost-effective option for NHL/HL/MM patients with poor response to SM regimens.